AK154
/ Akesobio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 10, 2025
Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer
(The Manila Times)
Trial status • Pancreatic Ductal Adenocarcinoma
1 to 1
Of
1
Go to page
1